{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:48:03Z","timestamp":1791913683720,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"vor","delay-in-days":39,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.canrad.2026.104858","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:41:08Z","timestamp":1790199668000},"page":"104858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypofractionated radiotherapy for localized prostate cancer: From phase III evidence to real-world outcomes with or without elective pelvic nodal irradiation"],"prefix":"10.1016","volume":"30","author":[{"given":"Charles","family":"Raynaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Jornet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Guillerm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Mongiat-Artus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Hermieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Desgrandchamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Qu\u00e9ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2026.104858_bib0165","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2026.104858_bib0170","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canrad.2026.104858_bib0175","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1016\/j.purol.2019.01.007","article-title":"Recommandations fran\u00e7aises du Comit\u00e9 de canc\u00e9rologie de l\u2019Afu\u2013Actualisation 2018-2020\u00a0: cancer de la prostate","volume":"28","author":"Rozet","year":"2018","journal-title":"Prog Urol"},{"key":"10.1016\/j.canrad.2026.104858_bib0180","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(24)00148-7","article-title":"Quantification of the environmental impact of radiotherapy and associated secondary human health effects: a multi-institutional retrospective analysis and simulation","volume":"25","author":"Lichter","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2026.104858_bib0185","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.canrad.2016.07.057","article-title":"Prostate Fractionated Irradiation Trial (PROFIT)\u00a0: r\u00e9sultats d\u2019une \u00e9tude internationale randomis\u00e9e comparant deux sch\u00e9mas d\u2019irradiation des cancers de prostate de risque interm\u00e9diaire","volume":"20","author":"Supiot","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104858_bib0190","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2026.104858_bib0195","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1200\/JCO.23.02445","article-title":"Long-term analysis of NRG Oncology RTOG 0415: a randomized phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2026.104858_bib0200","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"Van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2026.104858_bib0205","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial","volume":"22","author":"Fransson","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2026.104858_bib0210","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2026.104858_bib0215","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2026.104858_bib0220","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1200\/JCO.2006.10.5171","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma?. Update of the long-term survival results of the G\u00e9tug-01 randomized study","volume":"25","author":"Pommier","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2026.104858_bib0225","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0360-3016(94)90138-4","article-title":"Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer","volume":"28","author":"Roach","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2026.104858_bib0230","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ijrobp.2005.05.054","article-title":"Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer: long-term outcomes","volume":"63","author":"Kupelian","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2026.104858_bib0235","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.canrad.2026.104858_bib0240","first-page":"1009","article-title":"Is the \u03b1\/\u03b2 ratio for prostate tumours really low and does it vary with the level of risk at diagnosis?","volume":"33","author":"Fowler","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canrad.2026.104858_bib0245","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) v5. 0","author":"Anon","year":"2017"},{"key":"10.1016\/j.canrad.2026.104858_bib0250","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2026.104858_bib0255","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2026.104858_bib0260","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2018.07.003","article-title":"Optimal scheduling of hypofractionated radiotherapy for localized prostate cancer: A systematic review and metanalysis of randomized clinical trials","volume":"70","author":"Arcangeli","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.canrad.2026.104858_bib0265","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2018.77.9868","article-title":"Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer","volume":"36","author":"Hoffman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2026.104858_bib0270","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.eururo.2024.08.032","article-title":"Hypofractionated dose escalation radiotherapy for high-risk prostate cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial","volume":"87","author":"Niazi","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2026.104858_bib0275","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/COC.0000000000000241","article-title":"Hypofractionated versus standard fractionated proton-beam therapy for low-risk prostate cancer: interim results of a randomized trial PCG GU 002","volume":"41","author":"Vargas","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.canrad.2026.104858_bib0280","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.canrad.2026.104858_bib0285","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2025.09.067","article-title":"Hypofractionated dose escalation versus conventionally fractionated radiation therapy for patients with intermediate- and high-risk localized prostate cancer: long-term results of the HYPRO Trial","volume":"124","author":"Wiersma","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2026.104858_bib0290","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ijrobp.2005.05.054","article-title":"Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer: long-term outcomes","volume":"63","author":"Kupelian","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2026.104858_bib0295","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(25)00034-8","article-title":"Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium","volume":"26","author":"Kishan","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2026.104858_bib0300","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.euo.2025.10.009","article-title":"Radiotherapy plus long-term adjuvant androgen deprivation with a luteinizing hormone-releasing hormone antagonist versus agonist in patients with very high-risk localized or locally advanced prostate cancer: the EORTC GUCG-1414 phase 3 randomized trial","volume":"8","author":"Zilli","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.canrad.2026.104858_bib0305","first-page":"100846","article-title":"Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: a retrospective real-world single-center cohort study","volume":"48","author":"Kahlmeter Brandell","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104858_bib0310","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijrobp.2023.11.006","article-title":"Randomized trial of concomitant hypofractionated intensity modulated radiation therapy boost versus conventionally fractionated intensity modulated radiation therapy boost for localized high-risk prostate cancer (pHART2-RCT)","volume":"119","author":"Glicksman","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2026.104858_bib0315","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.ijrobp.2024.05.014","article-title":"Stereotactic body proton therapy versus conventionally fractionated proton therapy for early prostate cancer: a randomized, controlled, phase 3 trial","volume":"120","author":"Toesca","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2026.104858_bib0320","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.2340\/1651-226X.2025.44211","article-title":"Ultra-hypofractionated radiotherapy with focal boost for high-risk localized prostate cancer (HYPO-RT-PC-boost): in silico evaluation with histological reference","volume":"64","author":"Nilsson","year":"2025","journal-title":"Acta Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321826000612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321826000612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:03:47Z","timestamp":1791911027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321826000612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1278321826000612"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2026.104858","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated radiotherapy for localized prostate cancer: From phase III evidence to real-world outcomes with or without elective pelvic nodal irradiation","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2026.104858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}],"article-number":"104858"}}